Biosynthetic human insulin qualifies as mono-component insulin under chapter 3004 31 10 despite containing protamine

CESTAT Chennai dismissed the appeal regarding classification of imported insulin products. The dispute centered on whether biosynthetic human insulin qualified as mono-component insulin under chapter heading 3004 31 10 for exemption under Notification No. 12/2012 Customs. The tribunal held that mono-component refers to purity rather than source, and insulin manufactured using r-DNA technology qualifies as mono-component insulin despite containing protamine as a second component. The appellant was entitled to customs exemption as the classification is content-based, not source-based, distinguishing it from porcine and bovine insulin classifications.

---

---

Issues Involved:
1. Classification of imported insulin products as "mono-component insulin."
2. Eligibility for customs duty exemption under relevant notifications.
3. Interpretation of "mono-component insulin" in the context of technological advancements.

Issue-wise Detailed Analysis:

1. Classification of Imported Insulin Products as "Mono-component Insulin":

The primary issue was whether the imported insulin products, specifically human insulin and insulin analogues, could be classified as "mono-component insulin." The respondent claimed that these products were eligible for exemption under Notification No. 12/2012-Cus. and Notification No. 50/2017-Cus. as they were lifesaving drugs. The adjudicating authority concluded that there was no statutory definition for "mono-component insulin" and relied on expert opinions and scientific literature to classify the products under tariff entry 30043110. The products were developed using r-DNA technology, devoid of High Molecular Weight Protein (HMWP), and were thus considered "mono-component insulin."

The revenue, however, argued that the term "mono-component insulin" traditionally referred to insulin extracted from animal sources and purified using chromatographic techniques. They contended that insulin manufactured using r-DNA technology did not fit this classification and that the term "mono-component" was inconsistently used across different countries. The revenue also questioned the expert opinions relied upon by the respondent, arguing that they lacked evidentiary value.

The tribunal found that the term "mono-component" referred to the purity of insulin rather than its source. It noted that the department did not provide evidence of impurity levels exceeding the threshold for "mono-component insulin." The tribunal also considered the evolution of insulin manufacturing, including advancements in r-DNA technology, which allowed for the production of highly purified human insulin.

2. Eligibility for Customs Duty Exemption:

The respondent sought exemption from customs duty under specific notifications, claiming that their products qualified as "mono-component insulin." The revenue argued that the burden of proving eligibility for exemption rested with the respondent, citing several judicial precedents.

The tribunal emphasized that the interpretation of exemption notifications should consider technological advancements. It referred to previous judicial decisions that supported the inclusion of products developed through new technologies under existing exemption categories. The tribunal concluded that the respondent's products, developed using r-DNA technology, qualified as "mono-component insulin" and were entitled to the claimed exemptions.

3. Interpretation of "Mono-component Insulin" in the Context of Technological Advancements:

The tribunal addressed the interpretation of "mono-component insulin" by considering technological progress. It highlighted that static interpretations of tariff schedules and exemption notifications were inappropriate given the rapid advancements in technology. The tribunal relied on expert opinions and scientific literature to support its conclusion that the respondent's products met the criteria for "mono-component insulin."

The tribunal also considered the HSN Explanatory Notes, which indicated that insulin analogues, despite structural differences, could be classified under the same tariff heading as insulin. It noted that the classification was content-based rather than source-based, allowing for the inclusion of products developed through r-DNA technology.

In conclusion, the tribunal dismissed the revenue's appeal, affirming the classification of the respondent's products as "mono-component insulin" and their eligibility for customs duty exemption. The decision underscored the importance of adapting legal interpretations to accommodate technological advancements in product development.

---